Cadila Healthcare’s state-of-the-art manufacturing plant at Baddi, Himachal Pradesh, has successfully obtained the Establishment Inspection Report from the USFDA. This will now pave the way for further approval of products from this site.
Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
